Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

One Health targets rising demand in specialist foot and ankle care

Discover One Health Group's growth in the UK elective healthcare market, focusing on foot and ankle surgery, and how it presents investment opportunities...

June 5, 2025

GSK Plc launches second tranche of £2 billion Share Buyback

GSK plc launches a £2 billion share buyback program to enhance shareholder value, starting the second tranche valued at £0.45 billion on June 4, 2025...

June 4, 2025

One Health Group fast-tracks NHS patient referrals

May 30, 2025

Aptamer expands odour control collaboration with Unilever

Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market...

May 30, 2025

Hikma Pharmaceuticals upgraded to ‘BBB’ by Fitch with stable outlook

Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and strategic position...

May 29, 2025

Nuformix granted EU Orphan Drug Status for IPF treatment NXP002

Nuformix plc secures Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis, enhancing treatment options for this rare disease...

May 29, 2025

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

May 27, 2025

GSK Plc Nucala approved by FDA for Eosinophilic COPD

GSK's Nucala (mepolizumab) gains FDA approval as a crucial add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype...

May 23, 2025

HUTCHMED showcases new oncology data at ASCO 2025

HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors...

May 23, 2025

Compassionate gynaecology care with NHS efficiency

Experience advanced gynaecological care at One Health, where NHS expertise meets modern techniques for swift and effective treatment of women’s health conditions...

May 22, 2025

Precision-driven recruitment that accelerates clinical trial success

Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies...

May 22, 2025

Oxford Nanopore unveils tech and pipeline updates at London Calling 2025

Oxford Nanopore Technologies recently unveiled innovative updates at its London Calling conference, showcasing advancements in nanopore sequencing technology and its applications...

May 22, 2025

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF...

May 22, 2025

Poolbeg Pharma Making Pivotal Strides in Cancer and Metabolic Disease Innovation – Shore Capital

May 21, 2025

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs...

May 21, 2025

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...

May 20, 2025

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs...

May 20, 2025

Cizzle Biotechnology raises £150k to support cancer test rollout

Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe...

May 20, 2025

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy...

May 20, 2025

Poolbeg Pharma targets severe flu and cytokine storms

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy...

May 19, 2025

News and Interview Alerts

Company Presentations

TEAM plc poised for future growth (VIDEO)

Pennant International Group Investor Presentation with CEO Philip Walker

Open Orphan Investor Presentation – 2021 a good year, 2022 will be a great year

Ferro-Alloy Resources Investor Presentation 2022

Q&As

Hardman & Co

NB Private Equity Partners 2025 CMD: good returns from low-risk PE model

10 December 2025

Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty

2 December 2025

Volta Finance: Liquid access to outperforming private credit

6 October 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Chesnara Plc: Showing good operational progress

8 September 2025

Green News

Drax expands FlexGen platform with Flexitricity acquisition

21 January 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

BrokerTalk

Quadrise Strengthens Position in Central America with Panama Trial Success – VSA Capital

24 September 2025

Lords Group Trading Share Price Tipped to Double on Positive 1H25 Results, Cavendish

19 September 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Finseta Pushes Forward with Strategic Growth Plans Despite Interim Setback – Shore Capital

11 September 2025

Funds

CQS Natural Resources Growth & Income plc

CQS Natural Resources Growth and Income double-digit NAV and share price gains in Dec 2025

22 January 2026

RECI reports strong longer-term NAV performance to December 2025

20 January 2026

Oil’s slide creates opening as market sentiment shifts | Ruffer Investment Company

16 January 2026

How FCSS is harnessing China’s innovation – Kepler Research

15 January 2026

View all Funds, Market Insights and news >>

FTSE 100 News

UK Broker Ratings

Spire Healthcare Group PLC (SPI.L) Stock Analysis: Navigating a 48.47% Potential Upside Amid Market Challenges

22 January 2026

Dr. Martens PLC (DOCS.L) Stock Analysis: Exploring the 35% Potential Upside in a Challenging Market

22 January 2026

Syncona Limited (SYNC.L) Stock Analysis: Analyst Consensus Points to Stunning 104% Upside

22 January 2026

Senior plc (SNR.L) Stock Analysis: Navigating the Aerospace & Defense Landscape with a 2.7% Upside

22 January 2026

Softcat PLC (SCT.L) Stock Analysis: A Strong ROI with 28% Potential Upside for Tech Investors

22 January 2026

November 24, 2025

One Health targets rising demand in specialist foot and ankle care

Discover One Health Group's growth in the UK elective healthcare market, focusing on foot and ankle surgery, and how it presents investment opportunities...

June 5, 2025

GSK Plc launches second tranche of £2 billion Share Buyback

GSK plc launches a £2 billion share buyback program to enhance shareholder value, starting the second tranche valued at £0.45 billion on June 4, 2025...

June 4, 2025

One Health Group fast-tracks NHS patient referrals

May 30, 2025

Aptamer expands odour control collaboration with Unilever

Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market...

May 30, 2025

Hikma Pharmaceuticals upgraded to ‘BBB’ by Fitch with stable outlook

Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and strategic position...

May 29, 2025

Nuformix granted EU Orphan Drug Status for IPF treatment NXP002

Nuformix plc secures Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis, enhancing treatment options for this rare disease...

May 29, 2025

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

May 27, 2025

GSK Plc Nucala approved by FDA for Eosinophilic COPD

GSK's Nucala (mepolizumab) gains FDA approval as a crucial add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype...

May 23, 2025

HUTCHMED showcases new oncology data at ASCO 2025

HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors...

May 23, 2025

Compassionate gynaecology care with NHS efficiency

Experience advanced gynaecological care at One Health, where NHS expertise meets modern techniques for swift and effective treatment of women’s health conditions...

May 22, 2025

Precision-driven recruitment that accelerates clinical trial success

Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies...

May 22, 2025

Oxford Nanopore unveils tech and pipeline updates at London Calling 2025

Oxford Nanopore Technologies recently unveiled innovative updates at its London Calling conference, showcasing advancements in nanopore sequencing technology and its applications...

May 22, 2025

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF...

May 22, 2025

Poolbeg Pharma Making Pivotal Strides in Cancer and Metabolic Disease Innovation – Shore Capital

May 21, 2025

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs...

May 21, 2025

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...

May 20, 2025

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs...

May 20, 2025

Cizzle Biotechnology raises £150k to support cancer test rollout

Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe...

May 20, 2025

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy...

May 20, 2025

Poolbeg Pharma targets severe flu and cytokine storms

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy...

May 19, 2025